Today: 8 June 2026
Browse Category

NYSE:NSC 28 September 2025 - 29 May 2026

Union Pacific’s $85 Billion Norfolk Southern Merger Faces a New Walk-Away Test

Union Pacific’s $85 Billion Norfolk Southern Merger Faces a New Walk-Away Test

Union Pacific warned it could drop its $85 billion bid for Norfolk Southern if U.S. regulators require major line sales or trackage rights as merger conditions. The Surface Transportation Board is still reviewing whether the revised application is complete, with a May 8 deadline for comments. CSX and other rivals have stepped up opposition, citing reduced competition. Union Pacific may owe Norfolk Southern a $2.5 billion fee if it walks away.
4 May 2026
··
Norfolk Southern Stock Slips as Fuel Shock Puts Its Profit Story to the Test

Norfolk Southern Stock Slips as Fuel Shock Puts Its Profit Story to the Test

Norfolk Southern reported first-quarter net income of $547 million, down from $750 million a year earlier, citing higher fuel costs and merger expenses. Revenue held steady at $3.0 billion, but operating income dropped to $877 million. Shares fell 0.5% as investors focused on fuel price pressures and weak freight volumes. Intermodal traffic slipped 4%, while coal tonnage rose 9% but brought in less revenue.
24 April 2026
···
Union Pacific stock price rises 2% as UNP tracks rail rally; merger deadline in focus

Union Pacific stock price rises 2% as UNP tracks rail rally; merger deadline in focus

Union Pacific shares rose 2.2% to $240.34 Tuesday afternoon, rebounding from a session low after earlier declines. CSX, Norfolk Southern, and Canadian Pacific Kansas City also gained. Investors are focused on the regulatory review of Union Pacific’s proposed merger with Norfolk Southern and freight demand projections for 2026. The Surface Transportation Board returned the merger application last month, citing missing data.
3 February 2026
·····
Union Pacific stock jumps 3% as earnings near and Norfolk Southern merger reset stays in focus

Union Pacific stock jumps 3% as earnings near and Norfolk Southern merger reset stays in focus

Union Pacific shares rose about 3% to $228.42 Wednesday as rail stocks rallied ahead of the company’s Jan. 27 earnings release. Regulators last week ordered Union Pacific and Norfolk Southern to revise their $85 billion merger filing, citing missing details. The Surface Transportation Board set a Feb. 17 deadline for the companies to respond. CSX and Norfolk Southern shares also gained nearly 3%.
21 January 2026
···
Union Pacific stock slips as rivals press regulators to reject Norfolk Southern merger filing; UNP sets Q4 earnings date

Union Pacific stock slips as rivals press regulators to reject Norfolk Southern merger filing; UNP sets Q4 earnings date

Union Pacific shares closed down 0.6% to $233.11 after rival railroads asked regulators to reject its merger application with Norfolk Southern as incomplete. The Surface Transportation Board is reviewing whether the $85 billion deal’s filing meets requirements, with a decision expected after Jan. 2. Canadian Pacific Kansas City and CSX cited missing data and insufficient detail on competition impacts. Union Pacific will report fourth-quarter results Jan. 27.
31 December 2025
····
Industrials Stocks Outlook: Defense, Transport, and Capex Themes Head Into the Final Week of 2025

Industrials Stocks Outlook: Defense, Transport, and Capex Themes Head Into the Final Week of 2025

U.S. industrials stocks held gains in thin post-holiday trading, with the sector seen as a year-end leader despite light volume. Defense shares drew attention after China imposed new sanctions on U.S. firms tied to Taiwan arms sales. The broader market closed slightly lower Friday, tracking the seasonal “Santa Claus rally” period. Investors are watching defense spending, transport demand, and business investment as 2026 approaches.
27 December 2025
···········
Union Pacific (UNP) Stock After Hours Today (Dec. 24, 2025): Merger Scrutiny, Holiday-Thin Trading, and What to Watch Before the Next Market Open

Union Pacific (UNP) Stock After Hours Today (Dec. 24, 2025): Merger Scrutiny, Holiday-Thin Trading, and What to Watch Before the Next Market Open

Union Pacific closed at $235.05 on Dec. 24, up 0.38% in a holiday-shortened session, then slipped to $234.34 in after-hours trading. U.S. markets will remain closed Dec. 25 for Christmas. The Surface Transportation Board set Dec. 29 as the deadline for comments on Union Pacific’s merger application with Norfolk Southern.
25 December 2025
····
Union Pacific (UNP) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Union Pacific (UNP) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Union Pacific shareholders approved the proposed Norfolk Southern acquisition with 99.5% of votes cast, representing nearly 80% of outstanding shares. The companies plan to file their formal merger application with the Surface Transportation Board on Dec. 19. UNP closed Friday at $239.95, up 1.62%, with after-hours trading flat near $240. The STB has classified the deal as a major merger, signaling a lengthy review.
15 December 2025
··
Union Pacific (UNP) Stock on December 1, 2025: Merger Risks, Dividend Strength and Wall Street’s 2026 Price Targets

Union Pacific (UNP) Stock on December 1, 2025: Merger Risks, Dividend Strength and Wall Street’s 2026 Price Targets

Union Pacific closed at $231.36 on December 1, 2025, valuing the company at $137 billion, with shares trading between $204.66 and $256.84 over the past year. Q3 adjusted EPS rose 12% to $3.08, net income climbed 9% to $1.8 billion, and operating revenue reached $6.24 billion. The company faces elevated regulatory and merger risk as it pursues an $85 billion Norfolk Southern deal.
1 December 2025
····
5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

5 NYSE Stocks to Watch Today (November 14, 2025): WMT, MRK, BMY, NSC, VRT

Walmart shares dropped up to 3% after the company named John Furner as CEO, replacing Doug McMillon effective February 2026. Merck agreed to buy Cidara Therapeutics for $9.2 billion in cash, gaining access to a late-stage flu prevention drug. U.S. equity futures fell sharply as tech stocks continued to slide and traders lowered expectations for a near-term Fed rate cut.
14 November 2025
·····
CSX CEO Abruptly Departs Amid Rail Merger Frenzy – What’s Next?

CSX Delivers Earnings Surprise: Stock Jumps as New CEO Navigates Rail Merger Frenzy

CSX shares rose about 3% to $36–$37 after reporting adjusted Q3 profit of $0.44 per share, beating expectations. Revenue matched forecasts at $3.59 billion as higher intermodal volumes offset weak coal demand. Net income fell 22% year-over-year due to one-time charges. The report marked Steve Angel’s first quarter as CEO following a recent leadership shakeup.
17 October 2025
····
CSX CEO Abruptly Departs Amid Rail Merger Frenzy – What’s Next?

CSX CEO Abruptly Departs Amid Rail Merger Frenzy – What’s Next?

CSX named Steve Angel as its new President and CEO, effective Sept. 28, replacing Joe Hinrichs after investor pressure for leadership change and potential rail consolidation. The move follows hedge fund Ancora Holdings’ public criticism of CSX’s performance and calls for a merger. Angel previously led Praxair and Linde. The announcement comes as industry rivals Union Pacific and Norfolk Southern pursue an $85 billion merger.
29 September 2025
······
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

The Federal Reserve cut rates by 25 basis points to 4.00–4.25% in mid-September, citing slowing growth as inflation remains above target. The S&P 500 is up about 13% in 2025, but strategists warn valuations are high. Compass agreed to buy Anywhere for $4.2 billion in stock, sending Anywhere shares up nearly 49%. The U.S. implemented a new auto trade pact with the EU, lowering tariffs to 15% as of August 1.
28 September 2025
·············

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop